Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

Stock Information for Cingulate Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cingulate Inc.

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
FDA Accepts Cingulate's New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.